Rinvoq® (upadacitinib) – New indication
October 21, 2022 - AbbVie announced the FDA approval of Rinvoq (upadacitinib), for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to tumor necrosis factor (TNF) blocker therapy.
Top